Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
One Percent Rule Checklist For Safer Forex Trading Risk 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
WALTHAM, Mass., April 19, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its first quarter 2017 financial results will be released on Tuesday, May 2, 2017 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: (877) 412-6083
International Dial-in Number: (702) 495-1202
Conference ID: 3903846
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 3903846
A telephone replay will be available from approximately 11:00 a.m. ET on May 2, 2017 through midnight on May 9, 2017.
The webcast with slides will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will be archived on the website for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of women’s and maternal health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
